Navigation Links
Cepheid to Webcast Upcoming Financial Presentations
Date:2/1/2012

SUNNYVALE, Calif., Feb. 1, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

Leerink Swann Global Healthcare Conference, New York, NY
Wednesday, February 15, 2012 at 11.30 a.m. Eastern Time

Raymond James Annual Conference, Orlando, FL
Tuesday, March 6, 2012 at 1.05 p.m. Eastern Time

Additionally, Cepheid announced that it will participate in The NASDAQ Opening Bell ceremony at The NASDAQ Stock Market on Tuesday, February 7, 2012. The ceremony commemorates the continued growth and innovation of Cepheid's GeneXpert® system which saw record placements in 2011, and will take place at 9:30 a.m. Eastern Time at The NASDAQ MarketSite Studio in Times Square, New York City.

Accessing Live Webcasts To access the live webcasts for the two investor conferences, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcasts will be available shortly following the presentation and will remain available for at least 90 days.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com

CONTACTS:

 

  For Media Inquiries: For Investor Inquiries:  

Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400-8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400-8329

investor.relations@cepheid.com

 

 


'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Reports Fourth Quarter and Full Year 2011 Results
2. Cepheid Welcomes Senior Vice President of Human Resources
3. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
4. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
5. Cepheid to Webcast Upcoming Financial Presentations
6. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
7. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
8. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
9. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
10. Cepheid Reports 2009 First Quarter Results
11. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion ... of bioprocess media products engineered to radically streamline culture processes, minimize processing ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. ... and expansion clinical trial for its lead drug candidate, AC0010, at the World ... trial was to determine the safety, antitumor activity, and recommended phase II dosage ...
(Date:12/7/2016)... /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast ... the Company,s Annual and Special Meeting. The ... on Thursday, December 15, 2016 at Mount Royal ... 4825 Mount Royal Gate SW, Calgary, Alberta ... and management information circular, containing the matters to be considered ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):